

Professional Experience

2015-today: Owner, Freelance consultant, EGOS. Modiin, Israel.

Consulting services in the field of biotechnology and pharma.

- Technology reviews and reports
- Strategic consulting
- Business development services
- Medical and scientific translation services
- Scientific writing services

2010-2015: COO, Eventus Diagnostic (Israel) LTD. Ora, Israel.

The company developed and produced the first to market blood based test for cancer diagnosis based on autoantibodies. The company had a total of 16 employees. Raised a total of 14M\$ for the development of this technology and achieved CE, Israeli MOF approval, and started initial sales.

Job description includes managing all operational activities (managing a team of 12) and reporting to the BoD on a monthly (written) /quarterly (meeting) basis:

- R&D supervision.
- Global Clinical trials infrastructure establishment and maintenance.
- QA and regulation strategy design and implementation.
- Patent and IP strategy design and implementation.
- Establish production line.
- Product and customer support activities (scientific publications and presentations).
- Business development activities – fundraising presentations, market/marketing activities.

2006-2010: R&D manager, Lab-discoveries LTD. Ora, Israel.

The company developed a platform technology for antibody based cancer diagnosis blood tests.

Job description includes managing the following activities:

- R&D – Managing scientific work and personnel.
- Global Clinical studies – responsible for all aspects of the global clinical studies.
- QA - Receiving ISO 9001 and ISO 13485.
- Patent and IP strategy – Designing the patent strategy of the company
- Business development activities.

2004-2006: R&D Project manager, NuAce Technologies Ltd., Rehovot, Israel.

The company was engaged in the establishment of a novel platform technology (designing, assimilation and control) for the production of *second generation aptamers*.

Job description included managing all R&D activities related to this project, including a small working team.

Education

1999-2004: Ph. D. degree, Feinberg Graduate School, The Weizmann Institute of Science, Rehovot. Thesis subject: *Recognition of the mRNA reading frames in the nucleus*. Supervisor: Prof. Joseph Sperling.

1997-1998: M. Sc. Degree, Feinberg Graduate School, The Weizmann Institute of Science, Rehovot. Thesis Subject: *Synthetic Peptides Derived From The Protein BRCA1*. Supervisor: Prof. Mati Fridkin.

1993-1996: B. Sc. degree in chemistry with honor. Faculty of Chemistry Tel-Aviv University, Tel-Aviv.

1989-1990: Economics and CPA, first year, Tel Aviv University (in the route of "Atuda"). Completion of first year and joining the army.

Professional courses

- Financial management – LAHAV executive education, Recanati business school, Tel Aviv University (2013).
- The 7th course of Health Care Technological Innovation - From Idea to Commercialization - LAHAV executive education, Recanati business school, Tel Aviv University (2013).
- Regulatory requirements of the FDA Medical device – Bioforum, Israel
- GCP – Bioforum, Israel (2014).
- ISO 9001 overview – The Standards Institute of Israel (2014).
- Let's start-up (2015) – lean startup business model, Maof, Modiin, Isarel.

Publications

- Allweis T*, Strauss L, Malyutin Z, Kapov-Kagan A, Novikov I, Bevers T, Iacobelli S, Sandri M, Bitterman A, Engelman P, Piura B, Rosenberg M, **Yahalom G***. (2015). *An Autoantibody Based Protein Microarray Blood Test to Enhance the Specificity of a Negative Screening Mammogram*. Advances in Breast Cancer Research; 2015:4 22-38. doi: 10.4236/abcr.2015.41003.
- **Yahalom G**, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM. (2013). *An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis*. Biomarkers in Cancer; 2013:5 71–80 doi:10.4137/BIC.S13236.
- Grassadonia A, Tinari N, Natoli C, **Yahalom G**, Iacobelli S. (2013). *Circulating autoantibodies to LGALS3BP: a novel biomarker for cancer*. Dis Markers; 2013:35(6) 747-52. doi: 10.1155/2013/214595. Epub 2013 Nov 18.
- Kamhi E*, **Yahalom G***, Kass G, Hacham Y, Sperling R, Sperling J. (2006). *AUG sequences are required to sustain nonsense-codon-mediated suppression of splicing*. Nucleic Acids Research; 34(12) 3421–3433.
- Li B, Wachtel C, Miriami E, **Yahalom G**, Friedlander G, Sharon G, Sperling R, Sperling J. (2002). *Stop codons affect 5' splice site selection by surveillance of splicing*. PNAS; 99 5277-5282.
- Delaney JK, **Yahalom G**, Sheves M, Subramaniam S. (1997). *Reducing the flexibility of retinal restores a wild-type-like photocycle in bacteriorhodopsin mutants defective in protein-retinal coupling*. PNAS; 94(10) 5028-33.

*Equal contribution

Patent applications

- G. Yahalom, A. Hayka (2009). A method and system for the detection of cancer .US application no. 61/219539, PCT/IL20101000498

Lectures and posters

- *"Start codons recognition is required for 5' splice site selection"*. The 8th annual meeting of the RNA society, Vienna, Austria, 7/2003.
- *Synthetic 5' splice sites are chosen only when not preceded by in frame stop codons*. The fifth symposium of post-transcriptional events and RNA fate, Maagan, Israel 5/2003.
- *Recognition of open reading frames by the pre-mRNA splicing machine*. FISEB (Federation of Israel Societies for Experimental Biology) 2002, Eilat, Israel, 2/2002.

Awards

- The Exact Sciences Dean's Honor 1995 and 1996, Tel-Aviv University, Tel-Aviv.

Languages

- Hebrew - reading, writing and speaking fluently.
- English - reading, writing and speaking fluently.

Army service

- 1990-1992, Compulsory service, rank sergeant.

Miscellaneous

Born 1971, Married+2, live in Modiin.